Jade Biosciences, Inc. Common Stock
JBIOJade Biosciences, Inc. (JBIO) is a biotechnology company focused on developing innovative solutions in the fields of cell therapy and regenerative medicine. The company leverages advanced biotechnologies to create therapeutic products aimed at improving patient outcomes in various medical conditions. Through research and development, Jade Biosciences seeks to advance treatment options by combining scientific innovation with clinical applications.
Company News
Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Dr. Mark Eisner, M.D., M.P.H., to its Board of Directors effective June 25, 2026. Dr. Eisner brings over 25 years of leadership experience in clinical development and immunology, including previous roles as Chief Medical Officer at Vir Biotechnology, Sonoma Biotherapeutics, and Fi...
U.S. stock futures showed mixed performance on Thursday with the S&P 500 and Nasdaq 100 declining while the Dow Jones gained. Key movers included CrowdStrike surging on a 4-for-1 stock split announcement, Broadcom falling despite beating earnings estimates, and PVH plummeting after disappointing guidance. The House passed a war powers resolution ...
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech company focused on autoimmune diseases, announced the pricing of a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The offering is expected to close on June 5, 2026, with net proceeds to be used for clinical trials, preclinical studies, man...
Jade Biosciences reported positive interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy treatment. The drug demonstrated ~70% IgA reductions sustained at 12 weeks with a favorable safety profile and potential for every-12-week dosing. Phase 2 trials are underway with Phase 3 expected to initiate in H1 2027.
Jade Biosciences announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026. As part of the appointment, Dr. Conner received 500,000 non-qualified stock options with an exercise price of $25.38 per share, vesting over four years. The company is a clinical-stage biotech focused on autoimmune disease ther...
